{"id":2338,"date":"2026-03-30T07:00:00","date_gmt":"2026-03-29T23:00:00","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=2338"},"modified":"2026-03-28T23:19:51","modified_gmt":"2026-03-28T15:19:51","slug":"hanchorbio-to-present-at-wic-apac-2026-sharing-perspectives-on-next-generation-immunotherapy-design","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-to-present-at-wic-apac-2026-sharing-perspectives-on-next-generation-immunotherapy-design\/","title":{"rendered":"HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era"},"content":{"rendered":"

HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era<\/strong><\/h2>\n

Presentation highlights engineered CD47\u2013SIRP\u03b1 blockade and combination-ready checkpoint design<\/em><\/h3>\n

 <\/p>\n

[Taipei, Shanghai, San Francisco<\/strong> | March 30, 2026<\/strong>] \u2013 HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced that Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented at WIC-APAC 2026 in Taipei on March 29, 2026.<\/p>\n

\"\"<\/p>\n

In the presentation, \u201cReprogramming the CD47-SIRP\u03b1 Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering<\/em>,\u201d Dr. Luk argued that the CD47 field is now being redefined less by target validation than by therapeutic design. The presentation highlighted a key translational lesson from first-generation CD47 programs: biologic relevance was established, but on-target hematologic toxicity constrained the therapeutic window and limited clinical utility.<\/p>\n

 <\/p>\n

Dr. Luk further discussed how engineered SIRP\u03b1-Fc approaches may help address that challenge by preserving macrophage-mediated antitumor activity while improving hematologic tolerability, sustaining target engagement, and enabling more clinically usable combination strategies. He also placed this design logic in a broader strategic context, positioning it as a foundation for next-generation multi-checkpoint therapeutics spanning innate and adaptive immunity.<\/p>\n

 <\/p>\n

\u201cFirst-generation CD47 programs helped establish the biologic relevance of the pathway, but they also made clear that hematologic liability was the critical translational barrier,\u201d said Dr. Luk. \u201cThe opportunity now is not simply to revisit the mechanism, but to redesign it \u2013 preserving meaningful innate immune activity while building molecules with a wider therapeutic window and greater combination potential.\u201d<\/p>\n

 <\/p>\n

During the session, Dr. Luk emphasized HanchorBio\u2019s clinical and translational perspective on HCB101, an AI-guided, structurally engineered SIRP\u03b1-IgG4 Fc fusion protein designed to selectively block the CD47-SIRP\u03b1 axis while minimizing hematologic toxicity that limited earlier CD47-directed methods. He also discussed how this work might contribute to the development of broader multi-functional checkpoint programs based on HanchorBio\u2019s Fc-Based Designer Biologics (FBDB\u2122) platform.<\/p>\n

 <\/p>\n

WIC-APAC 2026 also marked Dr. Luk\u2019s first presentation of HanchorBio in Taiwan in his current leadership capacity.<\/p>\n

 <\/p>\n

Presentation Details<\/strong><\/p>\n

Conference:<\/strong> World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026)<\/p>\n

Date:<\/strong> March 29, 2026<\/p>\n

Location:<\/strong> Taipei, Taiwan<\/p>\n

Presentation Title:<\/strong> Reprogramming the CD47-SIRP\u03b1 Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering<\/em><\/p>\n

 <\/p>\n

This session was moderated by Dr. Peter Mu-Hsin Chang, an attending physician in the Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, and Associate Professor at the Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University. Dr. Chang specializes in head and neck cancer, medical oncology, and immunotherapy-related research, with extensive experience in clinical trials and translational medicine.<\/p>\n

 <\/p>\n

Speaker Profile<\/strong><\/p>\n

Dr. Luk is a global biotechnology executive with more than 30 years of leadership experience across translational medicine, clinical development, regulatory strategy, medical affairs, and strategic partnering. His career has focused on advancing innovative therapeutics from early development through global clinical execution, regulatory milestones, and commercialization across the U.S., EU, and Asia. At HanchorBio, he leads global corporate and development strategy and oversees clinical development, regulatory strategy, and medical affairs for the company\u2019s HCB portfolio, including HCB101 and HCB301.<\/p>\n

\u00a0<\/strong><\/p>\n

About WIC-APAC<\/strong><\/p>\n

The World Immunotherapy Council (WIC) is an international organization focused on advancing immunotherapy through scientific exchange and global collaboration. WIC-APAC brings together clinical experts, researchers, and healthcare professionals from across the Asia-Pacific region to discuss advances in cancer immunology and immunotherapy.<\/p>\n

 <\/p>\n

About HanchorBio<\/strong><\/p>\n

Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company\u2019s proprietary Fc-based designer biologics (FBDB\u2122) platform enables the design of multi-functional biologics with diverse targeting modalities intended to engage both innate and adaptive immune pathways. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through rational molecular engineering and scalable CMC strategies.<\/p>\n","protected":false},"excerpt":{"rendered":"

HanchorBio participated in the World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026), to be held on March 29, 2026, at the International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan. At the conference, Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (CMO) of HanchorBio (Group), and CEO of HanchorBio US, was invited to present his clinical perspectives on CD47\u2013SIRP\u03b1 in cancer immunotherapy, as well as the latest trends in next-generation multi-checkpoint engineering.<\/p>\n","protected":false},"featured_media":2342,"template":"","news-category":[36],"class_list":["post-2338","news","type-news","status-publish","has-post-thumbnail","hentry","news-category-events"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media\/2342"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2338"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}